Home >  Cardiology-CTVS >  Cardiology & CTVS Perspective >  2020 in a nutshell: The...

2020 in a nutshell: The hottest developments in the field of cardiology this year. Section 1. General and preventive cardiology

Written By :  dr. Abhimanyu Uppal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-12-24 07:15 GMT   |   Update On 2020-12-26 09:10 GMT
Advertisement

4. EVAPORATE (Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy) trial  

Icosapent ethyl 4 g/day reduces low attenuation plaque volume at 18 months compared with placebo among patients with known CAD, as assessed by cardiac CT angiography (CTA)

Eligible patients were randomized in a 1:1 fashion to either icosapent ethyl 4 g/day (n = 40) or placebo.

Advertisement

The results of this trial indicate that icosapent ethyl 4 g/day reduces low attenuation plaque volume compared with placebo at 18 months, as measured by cardiac CTA. In addition, there was a reduction in total plaque volume and other plaque parameters as well. In the setting of a small sample size, there was no difference in triglyceride levels. These results may help explain the cardiovascular benefit noted with icosapent ethyl in the REDUCE-IT trial. Source: European Heart Journal: Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J 2020;Aug 29

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

dr. Abhimanyu Uppal

Dr Abhimanyu Uppal completed his M. B. B. S and M. D. in internal medicine from the SMS Medical College in Jaipur. He got selected for D. M. Cardiology course in the prestigious G. B. Pant Institute, New Delhi in 2017. After completing his D. M. Degree he continues to work as Post DM senior resident in G. B. pant hospital. He is actively involved in various research activities of the department and has assisted and performed a multitude of cardiac procedures under the guidance of esteemed faculty of this Institute. He can be contacted at editorial@medicaldialogues.in.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

India's Unique CV Risk Profile: How to Decode the Role of Aspirin?

Identifying Aspirin Candidates for Primary Prevention: Focus on Men Aged 40- 50 with Metabolic Syndrome and Cardiometabolic Risk

Young, Diabetic, and at High CV Risk: Is It Time for Early Aspirin?

Management of Hypertension: How Innovative Packaging Can Improve Patient Outcomes?

Uncontrolled T2D in India: Valuable Consideration for Dapagliflozin Sitagliptin Combination

JAPI Releases Dedicated Supplement Addressing Clinical Needs for Adult Vaccination in India

Aspirin in Primary Prevention of Stroke-Review of Evidence Through the Needs of Indian Clinical Settings

Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension, Dyslipidemia, and Familial ASCVD Risk